Each 100 mL of R-Gene® 10 (10% Arginine Hydrochloride Injection, USP) for intravenous use contains 10 g of L-Arginine Hydrochloride, USP in Water for Injection, USP. L-arginine is a naturally occurring amino acid.
R-Gene® 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for HGH can be of diagnostic usefulness. It can be used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and problems of growth and stature.
If the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for HGH, a test with R-Gene® 10 is advisable to confirm the negative response. This can be done after a waiting period of one day. As patients may not respond to R-Gene® 10 (10% Arginine Hydrochloride Injection, USP) during the first test, the unresponsive patient should be tested again to confirm the negative result. A second test can be performed after a waiting period of one day. Some patients who respond to R-Gene® 10 do not respond to insulin and vice versa. The rate of false positive responses for R-Gene® 10 is approximately 32%, and the rate of false negatives is approximately 27%.
Published Studies Related to Arginine Injection
Oral L-arginine supplementation in patients with mild arterial hypertension and
its effect on plasma level of asymmetric dimethylarginine, L-citruline,
L-arginine and antioxidant status. 
CONCLUSIONS: L-arginine supplementation increases plasma arginine, citrulline and
Instant dentin hypersensitivity relief of a single topical application of an
in-office desensitizing paste containing 8% arginine and calcium carbonate: A
split-mouth, randomized-controlled study. 
Abstract Objective. The aim of this study was to evaluate the clinical efficacy
of an in-office desensitizing paste containing 8% arginine and calcium carbonate
relative to calcium carbonate alone in the reduction of dentin hypersensitivity
in a randomized, double-blind, split-mouth clinical trial...
Intravenous arginine and human skin graft donor site healing: a randomized controlled trial. [2011.05]
BACKGROUND AND AIMS: Studies evaluating the effect of arginine supplementation in human wound healing are inhomogeneous with conflicting results. This study aims to clarify the role of arginine supplementation in the healing of human skin graft donor sites... CONCLUSION: Intravenous arginine supplementation does not improve angiogenesis, reepithelialization or neutrophil influx in healing of human skin graft donor sites. Copyright (c) 2010 Elsevier Ltd and ISBI. All rights reserved.
Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. [2010.05.01]
PURPOSE: It is well known that hepatocellular carcinoma (HCC) is an arginine auxotroph due to argininosuccinate synthetase I deficiency. This study's purpose was to evaluate the effects of pegylated arginine deiminase (ADI) in terms of toxicity, tumor response, alpha-fetoprotein (AFP) levels, and serum arginine levels... CONCLUSION: Pegylated ADI is a promising drug that capitalizes on a significant enzymatic deficiency in HCC. It is safe, well tolerated, and may benefit patients with unresectable HCC.
L-arginine supplemented nondiluted blood cardioplegia: a clinical trial. [2010.04]
AIM: L-arginine was shown to improve protection of the myocardium during coronary artery bypass graft (CABG) surgery. The objective of the present study was to determine the concentration of L-arginine to obtain the most effective protection of the myocardium during CABG surgery... CONCLUSION: Nondiluted blood cardioplegic solution supplemented with 4 mmol/L of L-arginine was associated with a significant decrease of myocardial lactate release after aortic cross-clamping and reperfusion during CABG surgery.
Clinical Trials Related to Arginine Injection
Arginine Malaria Trial: Study of Adjunctive Arginine in Falciparum Malaria [Completed]
Acute falciparum malaria is associated with low plasma arginine and impaired nitric oxide
(NO) production. Both are associated with poor outcome. This study will examine the safety
and effect of escalating doses of arginine in falciparum malaria. It will determine whether
arginine can increase NO production and have an effect on NO-dependent physiological
measurements. The hypothesis is that arginine: will be safe in falciparum malaria; will
return plasma arginine concentration to normal/supranormal levels; will increase systemic and
exhaled NO; reduces oxidant stress; and improves a number of NO-dependent physiological
measures of relevance to malaria.
Effect of Creatine and L-Arginine on Endothelial Function [Completed]
The study is a double blind 2x2 factorial study. Patients with coronary disease will be
randomly be assigned to L-arginine (9 g/day), creatine 21 g/d, both, or neither dietary
supplement. The function of the endothelium will be tested using ultrasound before and after
each treatment. These studies will help us understand why the endothelium is abnormal in
patients with coronary artery disease and how L-arginine is acting on endothelial function.
L-Arginine Supplementation and Exercise; L-Arginine Supplementation and Renal Function [Completed]
Effectiveness of Arginine as a Treatment for Sickle Cell Anemia [Completed]
Sickle cell disease (SCD), also known as sickle cell anemia, is an inherited genetic disease
that can cause intense pain episodes. This study will evaluate the effectiveness of the
nutritional supplement arginine at improving blood cell function and disease symptoms in
people with SCD.
The Short Term Safety and Efficacy of Inhaled L-Arginine in Patients With Cystic Fibrosis [Recruiting]
Page last updated: 2013-02-10